Inogen Inc. (NASDAQ: INGN) announced the appointment of Vafa Jamali as an independent director to its board of directors, effective on the date of the company's 2026 annual meeting or June 15, whichever comes first.

Jamali previously served as chief executive officer of ZimVie, where he led the company's Nasdaq listing following its spin-out from Zimmer Biomet. He spent nearly 12 years at Covidien and Medtronic, most recently serving as senior vice president and president of the Respiratory, Gastrointestinal & Informatics division, a $3 billion business with 10,000 employees across four businesses and 14 manufacturing sites.

"Throughout his many years of leading medical device companies, Vafa has established a track record of driving strategic execution and delivering sustained growth," said Beth Mora, chairperson of the board.

The appointment comes in connection with a cooperation agreement between Inogen and Kent Lake Partners LP, Kent Lake PR LLC and Benjamin Natter. The agreement includes standstill, voting and other provisions and will be filed with the U.S. Securities and Exchange Commission as an exhibit to a Current Report on Form 8-K.

"We invested in Inogen because we believe the Company's innovative respiratory product portfolio is uniquely positioned to address growing and unmet patient needs," said Benjamin Natter, managing member of Kent Lake.

Beverly, Massachusetts-based Inogen develops, manufactures and markets respiratory therapy devices for patients with chronic respiratory conditions in homecare settings. Evercore is serving as financial advisor to the company, with Covington & Burling LLP as legal counsel and Joele Frank, Wilkinson Brimmer Katcher as strategic communications advisor.